Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

24 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
CDK4/6 signaling attenuates the effect of epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors in EGFR-mutant non-small cell lung cancer.
Hara N, Ichihara E, Kano H, Ando C, Morita A, Nishi T, Okawa S, Nakasuka T, Hirabae A, Abe M, Asada N, Ninomiya K, Makimoto G, Fujii M, Kubo T, Ohashi K, Hotta K, Tabata M, Maeda Y, Kiura K. Hara N, et al. Among authors: nakasuka t. Transl Lung Cancer Res. 2023 Oct 31;12(10):2098-2112. doi: 10.21037/tlcr-23-99. Epub 2023 Oct 26. Transl Lung Cancer Res. 2023. PMID: 38025818 Free PMC article.
VEGFR2 blockade augments the effects of tyrosine kinase inhibitors by inhibiting angiogenesis and oncogenic signaling in oncogene-driven non-small-cell lung cancers.
Watanabe H, Ichihara E, Kayatani H, Makimoto G, Ninomiya K, Nishii K, Higo H, Ando C, Okawa S, Nakasuka T, Kano H, Hara N, Hirabae A, Kato Y, Ninomiya T, Kubo T, Rai K, Ohashi K, Hotta K, Tabata M, Maeda Y, Kiura K. Watanabe H, et al. Among authors: nakasuka t. Cancer Sci. 2021 May;112(5):1853-1864. doi: 10.1111/cas.14801. Epub 2021 Mar 18. Cancer Sci. 2021. PMID: 33410241 Free PMC article.
SHP2 Inhibition Enhances the Effects of Tyrosine Kinase Inhibitors in Preclinical Models of Treatment-naïve ALK-, ROS1-, or EGFR-altered Non-small Cell Lung Cancer.
Kano H, Ichihara E, Watanabe H, Nishii K, Ando C, Nakasuka T, Ninomiya K, Kato Y, Kubo T, Rai K, Ohashi K, Hotta K, Tabata M, Maeda Y, Kiura K. Kano H, et al. Among authors: nakasuka t. Mol Cancer Ther. 2021 Sep;20(9):1653-1662. doi: 10.1158/1535-7163.MCT-20-0965. Epub 2021 Jun 22. Mol Cancer Ther. 2021. PMID: 34158345 Free article.
CD8+ T-cell Responses Are Boosted by Dual PD-1/VEGFR2 Blockade after EGFR Inhibition in Egfr-Mutant Lung Cancer.
Nishii K, Ohashi K, Tomida S, Nakasuka T, Hirabae A, Okawa S, Nishimura J, Higo H, Watanabe H, Kano H, Ando C, Makimoto G, Ninomiya K, Kato Y, Kubo T, Ichihara E, Hotta K, Tabata M, Toyooka S, Udono H, Maeda Y, Kiura K. Nishii K, et al. Among authors: nakasuka t. Cancer Immunol Res. 2022 Sep 1;10(9):1111-1126. doi: 10.1158/2326-6066.CIR-21-0751. Cancer Immunol Res. 2022. PMID: 35802887 Free article.
Efficacy of gilteritinib in comparison with alectinib for the treatment of ALK-rearranged non-small cell lung cancer.
Ando C, Ichihara E, Nishi T, Morita A, Hara N, Takada K, Nakasuka T, Watanabe H, Kano H, Nishii K, Makimoto G, Kondo T, Ninomiya K, Fujii M, Kubo T, Ohashi K, Matsuoka KI, Hotta K, Tabata M, Maeda Y, Kiura K. Ando C, et al. Among authors: nakasuka t. Cancer Sci. 2023 Nov;114(11):4343-4354. doi: 10.1111/cas.15958. Epub 2023 Sep 15. Cancer Sci. 2023. PMID: 37715310 Free PMC article.
Randomized study comparing mannitol with furosemide for the prevention of cisplatin-induced renal toxicity in non-small cell lung cancer: The OLCSG1406 trial.
Makimoto G, Hotta K, Oze I, Ninomiya K, Nakanishi M, Hara N, Kano H, Watanabe H, Hata Y, Nishii K, Nakasuka T, Itano J, Ninomiya T, Kubo T, Ohashi K, Ichihara E, Minami D, Sato A, Tabata M, Maeda Y, Kiura K. Makimoto G, et al. Among authors: nakasuka t. Asia Pac J Clin Oncol. 2021 Feb;17(1):101-108. doi: 10.1111/ajco.13423. Epub 2020 Sep 3. Asia Pac J Clin Oncol. 2021. PMID: 32885583 Clinical Trial.
24 results